Camacho-Toledano, Celia
Machín-Díaz, Isabel
Calahorra, Leticia
Cabañas-Cotillas, María
Otaegui, David
Castillo-Triviño, Tamara
Villar, Luisa María
Costa-Frossard, Lucienne
Comabella, Manuel
Midaglia, Luciana
García-Domínguez, José Manuel
García-Arocha, Jennifer
Ortega, María Cristina
Clemente, Diego
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/00355, PI21/00302, RD16-0015/0019, FI19/00132)
Fundación Merck Salud (FMS_2020_MS)
Esclerosis Múltiple España (REEM-EME-S5, REEM-EME_2018)
ADEMTO
ATORDEM
AELEM
Article History
Received: 24 August 2022
Accepted: 30 October 2022
First Online: 19 November 2022
Declarations
:
: All the animal manipulations were approved by the institutional ethical committee (<i>Comité Ético de Experimentación Animal del Hospital Nacional de Parapléjicos</i>), and all the experiments were performed in compliance with the European guidelines for animal research (EC Council Directive 2010/63/EU, 90/219/EEC, Regulation No. 1946/2003), and with the Spanish National and Regional Guidelines for Animal Experimentation (RD 53/2013 and 178/2004, Ley 32/2007 and 9/2003, Decreto 320/2010). The study with human samples was approved by the corresponding local ethics committees of the Ramón y Cajal hospital, Valle d’Hebron Hospital and Donostia Hospital, and informed written consent was obtained from all the participants in accordance with the Helsinki declaration.
: Not applicable.
: The authors declare no competing financial interests.